Shares in Idorsia Pharmaceuticals Ltd are on the rise after the Swiss biotech received US approval for daridorexant, its closely watched sleeping pill which has been shown to help users function normally the next day.
Idorsia In Dreamland With Insomnia Drug Approval
FDA Green Light For Daridorexant
The Swiss biotech has got the thumbs up in the US for its insomnia drug which will be sold as Quviviq and is expected to be provide serious competition for Merck & Co's rival dual orexin receptor antagonist Belsomra.
